<DOC>
	<DOCNO>NCT02185703</DOCNO>
	<brief_summary>The main purpose study evaluate impact treatment Chordate System S020 ( medical device ) acute migraine headache pain .</brief_summary>
	<brief_title>Chordate System S020 Acute Migraine Clinical Investigation</brief_title>
	<detailed_description>One single migraine attack treat either Chordate System S020 Chordate System placebo mode . After screen visit , 3 month treatment , eligible subject ask return center onset next moderate severe migraine attack . Subjects re-checked eligibility , randomize treat center ( treatment visit ) . The subject record response next 48 hour use diary card . A follow-up visit schedule 3 7 day treatment . In addition subject contact within 24 48 hour treatment initiation via telephone contact discuss health include new ongoing AEs .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Subjects migraine , without aura accord International Headache Society ( IHS ) classification ( International Classification Headache Disorders [ ICHD ] III beta ) . History 1 6 migraine attack per month least 12 previous month . At least 50 % previous migraine attack moderate severe pain intensity . History least 48 hour freedom headache migraine attack . The majority previous untreated migraine attack last least 8 hour . Migraine onset age 50 year . History ( within one year prior inclusion clinical investigation ) 15 headache day per month ( i.e . headache kind ) . More 6 day per month nonmigraine headache ( within one year prior inclusion clinical investigation ) . Unable distinguish migraine headache headache type onset migraine attack . Treatment Botox head/neck area within 6 month screen visit , screen treatment visit . Previously treat implantable stimulator implantable device head and/or neck . Pronounced anterior septal nasal deviation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>